Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Purines and pain mechanisms: recent developments.

Xue Jun Liu1, Michael W Salter

  • 1University of Toronto Centre for the Study of Pain, Programmes in Brain and Behaviour and Cell Biology, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.

Current Opinion in Investigational Drugs (London, England : 2000)
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An X-linked long non-coding RNA, PTCHD1-AS, and the core features of autism.

Nature·2026
Same author

Microglial reactivity and neuroinflammation-driven changes in motivational behaviors are regulated by Orai1 calcium channels.

Science signaling·2026
Same author

Recommendations for the inclusion and study of sex and gender in research.

Nature neuroscience·2025
Same author

Protein-protein interaction-interfering peptide rescues dysregulated NMDA receptor signaling.

JCI insight·2025
Same author

Microglia, sex, and pain: even more twists and turns ahead?

Pain·2025
Same author

Neural crest precursors from the skin are the primary source of directly reprogrammed neurons.

Stem cell reports·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Purinergic signaling through P1 and P2 receptors influences pain. Activating adenosine A1 receptors alleviates chronic pain, while inhibiting P2X3 receptors reduces pain behaviors, highlighting purinoceptors as drug targets.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Purines like adenosine and ATP act as endogenous ligands modulating pain.
  • They target P1 (adenosine) and P2 purinoceptors in peripheral and central nervous systems.
  • These receptors play crucial roles in pain transmission and hypersensitivity.

Purpose of the Study:

  • To review the roles of various purinoceptor subtypes in pain processing.
  • To identify potential molecular targets for novel pain therapeutics.

Main Methods:

  • Review of clinical and experimental animal studies on purinoceptor function in pain.
  • Analysis of evidence implicating specific subtypes (A1, P2X3, P2X7, P2Y1, P2Y2) in pain modulation.

Main Results:

Related Experiment Videos

  • Activation of P1 (adenosine) A1 receptors reduces inflammatory and neuropathic chronic pain.
  • Inhibition of P2X3 receptors effectively reduces pain behaviors in animal models.
  • Emerging evidence suggests P2X7, P2Y1, and P2Y2 receptors are involved in pain hypersensitivity.

Conclusions:

  • Multiple purinoceptor subtypes are differentially involved in pain processing.
  • These purinoceptors represent promising molecular targets for developing new pain medications.